此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

THE-0504 in Patients With Solid Tumors

2026年6月9日 更新者:Thena Biotech S.r.l.

NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors

Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.

研究概览

详细说明

The primary aim of the Phase 1 study is to define the Recommended Phase 2 dose and the Maximum Tolerated Dose of THE-0504, as well as to assess the safety and tolerability of escalating doses of THE-0504 administered intravenously to patients with different types of solid tumors. The study will also provide first data in humans concerning safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of THE-0504. For the first-in-human study, a model based on a classic 3+3 design following a modified Fibonacci sequence for dose escalation will be implemented. THE-0504 will be administered IV on day 1 and day 8 of a 21-day cycle. At the end of 21 days from the first treatment of the first patient, the treatment of the second patient of the first Cohort will begin (according to the dose-escalation schedule of the specific Cohort). Intra-patient dose escalation will be permitted to minimize the chance of sub-optimal dosing. The results of the Phase 1 study will drive the future clinical development of THE-0504 in Phase 2 and Phase 3 studies.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

Patients will be enrolled in the study if they meet all the following criteria:

  1. written informed consent obtained;
  2. both gender adult (≥ 18 years) patients;
  3. diagnosis of solid tumor. Preferably, but non-limited, tumor types are the following: Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Pancreas Adenocarcinoma (PaAdCa), Gastric Cancer (GC) and Triple Negative Breast Cancer (TNBrCa);
  4. measurable metastatic disease or locally advanced unresectable tumors;
  5. have exhausted all EMA-approved treatment options;
  6. ECOG Performance Status graded as 0 or 1;
  7. patients able to understand the full nature and the purpose of the trial, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire trial (ability to attend all the planned trial visits according to the time limits included) based on Investigator's judgement;
  8. adequate liver function as assessed by following laboratory tests to be conducted within 28 days before the first dose of study treatment:

    • Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for patients with documented Gilbert-Meulengracht Syndrome, or for patients with hyperbilirubinemia considered due to liver metastasis).
    • Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor);
  9. adequate kidney function as assessed by following laboratory test to be conducted within 28 days before the first dose of study treatment:

    • Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min per 1.73 m2 according to the CKD-EPI formula.

  10. adequate bone marrow function as defined as:

    • Hgb ≥ 9 g/dL
    • ANC ≥1.5x109/L
    • PLT≥100.0 x109/L
  11. Female patients of childbearing potential and male patients who are sexually active with women of childbearing potential will have to mandatorily use an appropriate method of contraception, according to the definition of Note 3 of ICH M3 Guideline, for the entire duration of the trial and for a minimum of 12 months after last administration of the IMP.

Exclusion Criteria:

Patients will not be enrolled if they meet any of the following criteria:

  1. pregnant (as determined by a blood pregnancy test at the screening visit) or lactating women;
  2. male patients who are willing to father children during the trial or in the 12 months after the end of IMP administration;
  3. additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy;
  4. have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor;
  5. ECOG Performance Status > 2;
  6. had not tolerated previously administered Top1 inhibitor treatments;
  7. known active CNS metastatic disease (patients with CNS metastases that are treated with radiotherapy and are stable for at least 28 days before study treatment start could be considered eligible);
  8. serious concurrent illness;
  9. Hgb < 9 g/dL;
  10. Transfusion dependent anemia with transfusion dependency of ≥3 months;
  11. Clinically significant iron metabolism disorders (e.g., sickle cell anemia) or use of iron chelators treatments;
  12. Iron overload, hereditary hemochromatosis and similar;
  13. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;
  14. Prolonged QTc interval;
  15. Multiple Sclerosis (MS) or other demyelinating disease, Eaton-Lambert syndrome, history of haemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;
  16. Non-healing wound(s), except for ulcerative lesions caused by the underlying neoplasm;
  17. History of severe allergic or anaphylactic reactions to previous protein-based therapy;
  18. Currently receiving anticoagulation therapy with warfarin;
  19. Known history of HIV infection, unless all the following are applicable:

    • receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥ 3 months prior to the planned first study intervention;
    • CD4 T-cell count > 350 cells/μL
    • CD4 T-cell nadir (lowest historical count) > 350 cells/μL, and • viral load confirmed as < 50 copies/mL.
  20. HBV infection, unless on stable anti-viral therapy for > 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable; and HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable;
  21. Known autoimmune disease, uncontrolled diabetes, vitiligo, or stable thyroid disease;
  22. Patients on chronic (more than 10 days) administration of systemic, high-dose corticosteroids (≥4 mg Dexamethasone or equivalent), not amenable for reduction or suspension;
  23. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations;
  24. History of drugs and/or alcohol abuse;
  25. Patients considered to be unsuitable to participate, in the Investigator's opinion, for any other reason (e.g. consequences of previous medical and/or surgical procedures or other medical or ethical reasons);
  26. Planned relocation during the study, which would make impossible to attend the scheduled visits and follow-ups;
  27. Concomitant participation in other clinical trials or participation in the evaluation of any investigational drugs/products up to 4 weeks before this trial (in any case, enrolment procedure should start only after the complete washout of the drugs/products under investigation**); or previous participation in the same trial or planned to receive other investigational products during the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:治疗臂
THE-0504 will be administered intravenously according to the treatment regimen specified in the protocol.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Assessment of Maximum Tolerated Dose (MTD)
大体时间:From enrollment to completion of Cycle 1 (each cycle is 21 days)
From enrollment to completion of Cycle 1 (each cycle is 21 days)
Assessment of Recommended Phase 2 Dose (RP2D)
大体时间:During dose escalation, at the end of cycle 1 (each cycle is 21 days)
During dose escalation, at the end of cycle 1 (each cycle is 21 days)

次要结果测量

结果测量
大体时间
Pharmacokinetic assessments of the IMP
大体时间:Pre-dose and up to 96 hours (30 minutes, 3 hours, 24 hours, 48 hours and 96 hours) post-dose of the first 3 Cycles (63 days)
Pre-dose and up to 96 hours (30 minutes, 3 hours, 24 hours, 48 hours and 96 hours) post-dose of the first 3 Cycles (63 days)
Uprising / incidence of anti-THE-05 antibodies (ADA)
大体时间:From baseline through Cycle 4 (84 days)
From baseline through Cycle 4 (84 days)
Objective Response Rate (ORR) according to RECIST 1.1
大体时间:From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
Progression-Free Survival (PFS)
大体时间:From enrollment until disease progression or death from any cause (assessed up to 36 months)
From enrollment until disease progression or death from any cause (assessed up to 36 months)
Overall Survival (OS)
大体时间:From first IMP administration until death from any cause (assessed up to 36 months)
From first IMP administration until death from any cause (assessed up to 36 months)
Rate of patients with Complete Response (CR) or Partial Response (PR) according to RECIST 1.1
大体时间:From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
From baseline until disease progression, death, withdrawal or initiation of subsequent anticancer therapy (assessed up to 36 months)
Assessment of safety profile of the product THE-0504
大体时间:From first IMP administration through 90 days after last IMP administration
From first IMP administration through 90 days after last IMP administration
ECOG Performance Status changes from baseline
大体时间:From baseline through 90 days after last IMP administration
From baseline through 90 days after last IMP administration

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Gennaro Daniele、Fondazione Policlinico Universitario Agostino Gemelli IRCCS

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年11月13日

初级完成 (估计的)

2027年5月1日

研究完成 (估计的)

2027年5月1日

研究注册日期

首次提交

2026年6月3日

首先提交符合 QC 标准的

2026年6月9日

首次发布 (实际的)

2026年6月12日

研究记录更新

最后更新发布 (实际的)

2026年6月12日

上次提交的符合 QC 标准的更新

2026年6月9日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

To the present date, only the sharing of the summary of the clinical results after 30 months from the study completion can be guaranteed.

Complete data from individual participants cannot be shared in scientific publications until intellectual property of the Investigational Medicinal Product is granted in all countries currently under evaluation.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅